| 2 | 48 | 3 |
 阅读 |
 下载 |
 被引 |
目的 研究血浆心脏型脂肪酸结合蛋白（heart-type fatty acid-binding protein, H-FABP）对非小细胞肺癌（nonsmall cell lung cancer, NSCLC）诊断及患者预后的价值。方法 回顾性分析2020年6月至2021年11月4海军军医大学第一附属医院收治的252例NSCLC患者（研究组）和270例非肺癌患者（对照组）的临床资料，采用受试者操作特征（receiver operating characteristic, ROC）曲线和Logistic回归分析分析血浆H-FABP水平在NSCLC诊断和预后评估中的价值。结果 血浆H-FABP水平诊断肺癌的曲线下面积（area under the curve, AUC）为0.74(95%CI:0.70～0.78, P<0.01)。有吸烟史、饮酒史、淋巴结转移以及TNM[T（肿瘤原发灶的情况，tumor）, N（区域淋巴结受累情况，node）, M（远处转移，metastasis）]分期较高的肺癌患者中血浆H-FABP水平较高（P>0.05）。单因素Logistic回归分析结果显示，年龄≥60岁、有吸烟史、有饮酒史、有淋巴结转移以及TNM分期Ⅲ/Ⅳ期、血浆H-FABP高水平与NSCLC患者预后不良有关（P<0.05）。多因素Logistic回归分析结果显示，年龄≥60岁、有吸烟史、有饮酒史、有淋巴结转移、TNM分期为Ⅲ/Ⅳ期、血浆H-FABP高表达均是NSCLC患者预后不良的独立危险因素（P<0.05）。结论 血浆H-FABP是NSCLC的诊断标志物，高水平的血浆H-FABP与NSCLC患者不良预后相关。
Abstract：Objective To study the value of plasma heart fatty acid-binding protein(H-FABP) in the diagnosis and prognosis evaluation of non-small cell lung cancer(NSCLC).Methods An analysis of the clinical data of 252 NSCLC patients(the study group)and 270 non-NSCLC patients(the control group) admitted to the First Affiliated Hospital of Naval Mmedical University from June 2020to November 2021 was made retrospectively. The receiver operating curve(ROC) and Logistic regression were used to analyze the value of plasma H-FABP levels in the diagnosis and prognosis evaluation of NSCLC.Results The area under the curve(AUC) of plasma H-FABP level in the diagnosis of NSCLC was 0. 74(95% CI: 0. 70-0. 78)(P<0. 01). The H-FABP expression levels in lung cancer patients with smoking/drinking history, lymph node metastasis, and higher tumor node metastasis(TNM) stages(stage III and IV) were obviously higher(P>0. 05). The results of univariate Logistic regression analyses showed that age ≥60 years old, smoking/drinking, lymph node metastasis, TNM stage III/IV and high expression of H-FABP were related with poor prognosis of NSCLC patients(P<0. 05). The results of multivariate Logistic regression analysis also revealed that age(≥ 60 years), smoking/drinking history, lymph node metastasis, TNM stage III/IV and high expression of H-FABP were all independent risk factors for poor prognosis of NSCLC patients(P<0. 05).Conclusion Plasma H-FABP is an early diagnostic marker of NSCLC and high level of H-FABP is related with poor prognosis of NSCLC patients.
[1] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2] Mao Y, Yang D, He J, et al.Epidemiology of lung cancer[J].Surg Oncol Clin N Am, 2016, 25(3):439-445.
[3] Nasim F, Sabath BF, Eapen GA. Lung cancer[J]. Med Clin North Am, 2019, 103(3):463-473.
[4] Behera M, Owonikoko TK, Gal AA, et al.Lung adenocarcinoma staging using the 2011 iaslc/ats/ers classification:a pooled analysis of adenocarcinoma in situ and minimally invasive adenocarcinoma[J].Clin Lung Cancer, 2016, 17(5):e57-e64.
[5] Cancer Genome Atlas Research Network.Comprehensive molecular profiling of lung adenocarcinoma[J]. Nature, 2014, 511(7511):543-550.
[6] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J].CA Cancer J Clin, 2015, 65(1):5-29.
[7] Neal RD, Sun F, Emery JD, et al. Lung cancer[J]. BMJ,2019, 365:I1725.
[8] Goldstraw P, Chansky K, Crowley J, et al.The IASLC lung cancer staging project:proposals for revision of the tnm stage groupings in the forthcoming(eighth)edition of the TNM classification for lung cancer[J].J Thorac Oncol, 2016, 11(1):39-51.
[9] Rami-Porta R, Bolejack V, Crowley J, et al.The IASLC lung cancer staging project:proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer[J].J Thorac Oncol, 2015, 10(7):990-1003.
[10] Das UN.Heart-type fatty acid-binding protein(H-FABP)and coronary heart disease[J].Indian Heart J, 2016, 68(1):16-18.
[11] Tang Z, Shen Q, Xie H, et al. Elevated expression of FABP3and FABP4 cooperatⅣely correlates with poor prognosis in nonsmall cell lung cancer(NSCLC)[J].Oncotarget, 2016, 7(29):46253-46262.
[12] Travis WD, Brambilla E, Noguchi M, et al.International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma[J].J Thorac Oncol, 2011, 6(2):244-285.
[13]Ferlay J, Colombet M, Soerjomataram I, et al.Estimating the global cancer incidence and mortality in 2018:GLOBOCAN sources and methods[J].Int J Cancer, 2019, 144(8):1941-1953.
[14] Lyu ZY, Li N, Chen SH, et al.Risk prediction model for lung cancer incorporating metabolic markers:development and internal validation in a Chinese population[J].Cancer Med, 2020, 9(11):3983-3994.
[15] Zeng H, Zheng R, Guo Y, et al.Cancer survival in China, 2003-2005:a population-based study[J].Int J Cancer, 2015, 136(8):1921-1930.
[16] Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification[J]. Chest, 2017, 151(1):193-203.
[17] Tammemagi MC, Katki HA, Hocking WG, et al.Selection criteria for lung-cancer screening[J].N Engl J Med, 2013, 368(8):728-736.
[18] Veronesi G, Maisonneuve P, Rampinelli C, et al.Computed tomography screening for lung cancer:results of ten years of annual screening and validation of cosmos prediction model[J]. Lung Cancer, 2013, 82(3):426-430.
[19] Muller DC, Larose TL, Hodge A, et al.Circulating high sensitivity C reactive e protein concentrations and risk of lung cancer:nested case-control study within lung cancer cohort consortium[J].BMJ, 2019, 364:k4981.
[20] Lyu Z, Li N, Wang G, et al.Independent and joint associations of blood lipids and lipoproteins with lung cancer risk in Chinese males:a prospective cohort study[J].Int J Cancer, 2019, 144(12):2972-2984.
[21] Okano T, Kondo T, Fujii K, et al. Proteomic signature corresponding to the response to gefitinib(Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma[J].Clin Cancer Res, 2007, 13(3):799-805.
[22] Van Der Wekken AJ, Hiltermann TJ, Groen HJ. The value of proteomics in lung cancer[J]. Ann Transl Med, 2015, 3(3):29.
[23] Zhang L, Cilley RE, Chinoy MR. Suppression subtractive hybridization to identify gene expressions in variant and classic small cell lung cancer cell lines[J].J Surg Res, 2000, 93(1):108-119.
[24] Hashimoto T, Kusakabe T, Sugino T, et al.Expression of hearttype fatty acid-binding protein in human gastric carcinoma and its association with tumor aggressiveness, metastasis and poor prognosis[J].Pathobiology, 2004, 71(5):267-273.
[25] Huynh HT, Larsson C, Narod S, et al.Tumor suppressor activity of the gene encoding mammary-derived growth inhibitor[J].Cancer Res, 1995, 55(11):2225-2231.
[26] Huynh H, Alpert L, Pollak M. Silencing of the mammary-derived growth inhibitor(MDGI)gene in breast neoplasms is associated with epigenetic changes[J].Cancer Res, 1996, 56(21):4865-4870.
基本信息:
DOI：
中图分类号:R734.2
引用信息:
[1]赵硕,王欣.血浆心脏型脂肪酸结合蛋白对非小细胞肺癌诊断和预后的价值研究[J].海军医学杂志,2023,44(03):246-250.
基金信息: